Lapatinib Ditosylate
别名: GW-572016 Ditosylate
中文名称:二苯磺酸拉帕替尼
目录号:S1028 Purity: 99.99%
Lapatinib Ditosylate是一种有效的EGFR 和 ErbB2抑制剂,在无细胞试验中IC50分别为10.8和9.2 nM。
CAS: 388082-77-7
客户使用Selleck的Lapatinib Ditosylate发表文献139篇
- Cancer Discov, 2022 12(1):204-219
- Nat Cell Biol, 2021 23(4):377-390
- Cancer Discov, 2020 10(5):674-687
- Cell Metab, 2018 28(6):817-832
- Cancer Cell, 2016 29(4):563-573
- Mol Cancer, 2015 14:72
- Cancer Cell, 2012 21(4):488-503
- NPJ Breast Cancer, 2024 10(1):65
- iScience, 2024 27(2):108839
- NAR Cancer, 2024 6(4):zcae041
- STAR Protoc, 2024 5(2):102987
- bioRxiv, 2024 2024.04.02.587656
- bioRxiv, 2024 2024.02.19.581073
- Nat Commun, 2023 14(1):3450
- Int J Mol Sci, 2023 24(7)6228
- Cancers (Basel), 2023 15(4)1216
- Noncoding RNA, 2023 9(3)31
- NAR Cancer, 2023 5(1):zcad001
- Biochem Biophys Rep, 2023 34:101436
- Nat Commun, 2022 13(1):6481
- Nat Chem Biol, 2022 10.1038/s41589-022-00984-x
- Cancer Res, 2022 can.21.2908
- Oncogene, 2022 41(43):4808-4822
- Breast Cancer Res, 2022 24(1):18
- Cell Oncol (Dordr), 2022 45(4):601-619
- Mol Cancer Ther, 2022 molcanther.0320.2021
- Mol Cancer Ther, 2022 21(5):751-761
- Front Pharmacol, 2022 13:1032975
- Int J Mol Sci, 2022 23(2)775
- Int J Mol Sci, 2022 23(10)5476
- J Cell Mol Med, 2022 10.1111/jcmm.17210
- Cancers (Basel), 2022 14(6)1537
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:813100
- Sci Rep, 2022 12(1):2711
- JCO Precis Oncol, 2022 6:e2100325
- Sci Rep, 2022 12(1):2928
- Pharmacol Rep, 2022 10.1007/s43440-022-00396-7
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- BMC Cancer, 2022 22(1):844
- Oncol Lett, 2022 23(6):177
- Breast Cancer (Dove Med Press), 2022 14:25-39
- Nat Commun, 2021 12(1):6667
- Cancer Lett, 2021 527:10-23
- Cell Death Dis, 2021 12(6):588
- J Transl Med, 2021 19(1):184
- Breast Cancer Res, 2021 23(1):81
- Oncogenesis, 2021 61-2021)
- Oncogenesis, 2021 10(9):61
- NPJ Breast Cancer, 2021 7(1):51
- NPJ Breast Cancer, 2021 7(1):79
- Int J Mol Sci, 2021 22(20)11199
- BMC Biol, 2021 19(1):228
- Cancers (Basel), 2021 13(14)3635
- Front Oncol, 2021 11:750852
- Sci Rep, 2021 11(1):10893
- Environ Toxicol, 2021 10.1002/tox.23125
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Cancer Med, 2021 10(7):2370-2379
- BMC Cancer, 2021 21(1):923
- PLoS One, 2021 16(2):e0236074
- Biochem Biophys Res Commun, 2021 567:154-160
- Nat Commun, 2020 11(1):4591
- Cancer Cell Int, 2020 19;20:58
- Front Pharmacol, 2020 11:601572
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Oncol Rep, 2020 44(3):1127-1135
- Clin Cancer Res, 2019 25(20):6243-6259
- J Exp Clin Cancer Res, 2019 38(1):236
- Cell Rep, 2019 28(9):2331-2344
- J Clin Med, 2019 8(12)
- Clin Cancer Res, 2018 24(18):4566-4578
- Cell Syst, 2018 6(3):329-342
- Oncotarget, 2018 9(9):8560-8572
- Mol Cancer Res, 2018 16(5):894-908
- Ann Thorac Surg, 2018 105(2):363-370
- Cancer Biol Ther, 2018 19(10):921-933
- Methods Mol Biol, 2018 1788:251-268
- Cancer Res, 2017 77(20):5554-5563
- Cell Syst, 2017 5(2):105-118
- Proteomics, 2017 10.1002/pmic.201600335
- Tumour Biol, 2017 39(3):1010428317695028
- Cancer Res, 2016 76(20):6095-6106
- Mol Cancer Ther, 2016 15(10):2486-2497
- Oncotarget, 2016 7(18):26551-66
- BMC Cancer, 2016 16(1):813
- BMC Cancer, 2016 16:678
- Cancer Invest, 2016 34(9):424-430
- Sci Transl Med, 2015 7(284):284ra57
- Cancer Res, 2015 10.1158/0008-5472.CAN-15-0370
- Cell Death Dis, 2015 6:e1699
- Mol Oncol, 2015 9(3):586-600
- Cell Cycle, 2015 14(7):1059-69
- Toxicol Appl Pharmacol, 2015 10.1016/j.taap.2015.05.001
- Org Biomol Chem, 2015 13(17):5006-11
- Nat Commun, 2014 5:3384
- Neuro Oncol, 2014 16(1):72-80
- Cancer Res, 2014 10.1158/0008-5472.CAN-14-0844
- Cancer Lett, 2014 342(1):82-91
- Oncogene, 2014 10.1038/onc.2014.153.
- Oncogene, 2014 10.1038/onc.2014.161.
- Oncogene, 2014 10.1038/onc.2014.106.
- Breast Cancer Res, 2014 16(3):R45
- Mol Cell Biol, 2014 34(20):3843-54
- Antimicrob Agents Chemother, 2014 10.1128/AAC.02393-14
- Drug Metab Dispos, 2014 42(11):1851-7
- PLoS One, 2014 9(10):e111146
- PLoS One, 2014 9(9):e106349
- J Mol Endocrinol, 2014 52(2):223-34
- Genes Cancer, 2014 5(7-8):261-72
- J Clin Invest, 2013 123(2):682-99
- Neuro Oncol, 2013 10.1093/neuonc/not152
- Cancer Lett, 2013 340(1):43-50
- Cell Cycle, 2013 12(18):2978-91
- Drug Metab Dispos, 2013 10.1124/dmd.113.054189
- Mol Pharmacol, 2013 83(4):882-93
- Invest New Drugs, 2013 31(6):1458-65
- Virginia Commonwealth University, 2013 2013
- ACS Nano, 2012 6(10):8525-35
- Proc Natl Acad Sci USA, 2012 109(17):6584-9
- Cancer Lett, 2012 316(1):77-84
- Cancer Lett, 2012 324(1):98-108
- Oncogene, 2012 32(37):4331-42
- Mol Oncol, 2012 7(3):392-401
- Mol Carcinog, 2012 52(12):959-69
- Anal Bioanal Chem, 2012 403(6):1685-95
- PLoS One, 2012 7(5):e36691
- Prostate, 2012 72(10):1140-9
- Br J Cancer, 2011 105(6):796-806
- Biochem Pharmacol, 2011 82(10):1457-66
- Mol Cancer Ther, 2011 10(10):1846-56
- Mol Cancer Ther, 2011 10(4):697-707
- Anticancer Res, 2011 31(11):3767-73
- Int J Proteomics, 2011 2011:215496
- Carcinogenesis, 2010 31(11):1948-55
- Methods Mol Biol, 2010 661:107-22
化学信息&溶解度
分子量 | 925.46 |
分子式 | C29H26ClFN4O4S.2C7H8O3S |
CAS号 | 388082-77-7 |
Smiles | CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 185 mg/mL ( 199.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 108.05 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 185 mg/mL ( 199.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 108.05 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 108.05 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
5%Tween80
53%ddH2O
浓度:1.25mg/ml
(1.35mM)
操作示例:以 1 mL 工作液为例,取20μL62.5mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入530μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。